Tanshinones: First-in-Class Inhibitors of the Biogenesis of the Type 3 Secretion System Needle of for Antibiotic Therapy
Overview
Authors
Affiliations
The type 3 secretion system (T3SS) found as cell-surface appendages of many pathogenic Gram-negative bacteria, although nonessential for bacterial survival, is an important therapeutic target for drug discovery and development aimed at inhibiting bacterial virulence without inducing antibiotic resistance. We designed a fluorescence-polarization-based assay for high-throughput screening as a mechanistically well-defined general strategy for antibiotic discovery targeting the T3SS and made a serendipitous discovery of a subset of tanshinones-natural herbal compounds in traditional Chinese medicine widely used for the treatment of cardiovascular and cerebrovascular diseases-as effective inhibitors of the biogenesis of the T3SS needle of multi-drug-resistant . By inhibiting the T3SS needle assembly and, thus, cytotoxicity and pathogenicity, selected tanshinones reduced the secretion of bacterial virulence factors toxic to macrophages , and rescued experimental animals challenged with lethal doses of in a murine model of acute pneumonia. As first-in-class inhibitors with a demonstrable safety profile in humans, tanshinones may be used directly to alleviate -associated pulmonary infections without inducing antibiotic resistance. Since the T3SS is highly conserved among Gram-negative bacteria, this antivirulence strategy may be applicable to the discovery and development of novel classes of antibiotics refractory to existing resistance mechanisms for the treatment of many bacterial infections.
Jiang C, Zheng L, Yan Y, Wang M, Liu X, Dai J ACS Appl Mater Interfaces. 2024; 16(32):41828-41842.
PMID: 39088848 PMC: 11331443. DOI: 10.1021/acsami.4c06665.
Using next generation antimicrobials to target the mechanisms of infection.
Gadar K, McCarthy R NPJ Antimicrob Resist. 2024; 1(1):11.
PMID: 38686217 PMC: 11057201. DOI: 10.1038/s44259-023-00011-6.
Ren X, Feng C, Wang Y, Chen P, Wang S, Wang J Exp Mol Med. 2023; 55(8):1757-1769.
PMID: 37524874 PMC: 10474099. DOI: 10.1038/s12276-023-01062-5.
Blasey N, Rehrmann D, Riebisch A, Muhlen S Front Cell Infect Microbiol. 2023; 12:1065561.
PMID: 36704108 PMC: 9872159. DOI: 10.3389/fcimb.2022.1065561.
Research Progress on Small Molecular Inhibitors of the Type 3 Secretion System.
Lv C, Li Y, Wei Y, Wang J, Yu H, Gao F Molecules. 2022; 27(23).
PMID: 36500441 PMC: 9740592. DOI: 10.3390/molecules27238348.